JEFFREY REINHART: Open Payments
NPI 1033105747 · MONTICELLO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,131 in 46 payments from 16 companies in 2025. Trend: 2023 $1,334 · 2024 $1,227 · 2025 $1,131
Food & beverage: $1,131
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $234 |
| ABBVIE INC. | 10 | $225 |
| Novo Nordisk Inc | 3 | $132 |
| Teva Pharmaceuticals USA, Inc. | 1 | $99 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $61 |
| Lundbeck LLC | 3 | $49 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $47 |
| PFIZER INC. | 3 | $47 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| GlaxoSmithKline, LLC. | 2 | $41 |
Products named: VRAYLAR, LOKELMA, AUSTEDO XR, Ozempic, FARXIGA, UBRELVY, CAPLYTA, REXULTI.
Industry payments across AR — which companies pay providers there.
